Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

ABC News chief medical correspondent Dr. Tara Narula breaks down what to know about a new study that says Zepbound may be ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Eli Lilly's tirzepatide leads to 50% more weight loss compared to Novo Nordisk's semaglutide in 72-week study.